Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS other · 2026-04-20

Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy [Phase 3]

View source ↗

Summary

Clinical trial update on a Phase 3 study evaluating Samelisant for narcolepsy; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Samelisant (SUVN-G3031)

Snippet

Sponsor: Suven Life Sciences Limited | Conditions: Narcolepsy | Phase 3 | Status: NOT_YET_RECRUITING